Experience in the Treatment of Irritable Bowel Syndrome Developed after a New Coronavirus Infection (COVID-19)
Aim. To study the effectiveness of Kolofort® (affinally purified antibodies to tumor necrosis factor α, to the brain-specific protein S-100 and to histamine) in patients with various variants of irritable bowel syndrome (IBS) that developed after a new coronavirus infection (COVID-19).Materials and...
Saved in:
Main Author: | R. G. Myazin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Gastro LLC
2022-05-01
|
Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
Subjects: | |
Online Access: | https://www.gastro-j.ru/jour/article/view/716 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
COVID-19 Pandemic and Irritable Bowel Syndrome — is there a Relationship?
by: V. A. Akhmedov
Published: (2022-08-01) -
Irritable Bowel Syndrome Onset after New Coronavirus Infection COVID-19
by: I. Yu. Feklina, et al.
Published: (2022-03-01) -
Postinfectious Irritable Bowel Syndrome: Polemic and Open Issues
by: A. A. Sheptulin, et al.
Published: (2022-03-01) -
Irritable Bowel Syndrome Diagnosis: Should There Be Alertness to Cancer?
by: A. A. Sheptulin, et al.
Published: (2019-05-01) -
The treatment of irritable bowel syndrome from the modern views on the disease pathogenesis
by: Ye. A. Poluektova, et al.
Published: (2013-03-01)